In:
Drug Development Research, Wiley, Vol. 12, No. 3-4 ( 1988-01), p. 267-270
Abstract:
Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.
Type of Medium:
Online Resource
ISSN:
0272-4391
,
1098-2299
DOI:
10.1002/ddr.430120309
Language:
English
Publisher:
Wiley
Publication Date:
1988
detail.hit.zdb_id:
1500191-X
SSG:
15,3
Permalink